CN102716134A - Application of oleanolic acid to medicine for treating obesity - Google Patents
Application of oleanolic acid to medicine for treating obesity Download PDFInfo
- Publication number
- CN102716134A CN102716134A CN2012101863470A CN201210186347A CN102716134A CN 102716134 A CN102716134 A CN 102716134A CN 2012101863470 A CN2012101863470 A CN 2012101863470A CN 201210186347 A CN201210186347 A CN 201210186347A CN 102716134 A CN102716134 A CN 102716134A
- Authority
- CN
- China
- Prior art keywords
- oleanolic acid
- obesity
- medicine
- obviously
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a purpose of oleanolic acid and belongs to an application of oleanolic acid to medicine for treating obesity. The oleanolic acid is injected into the abdominal cavities of db/db mice with obesity and diabetes, the blood sugar level can be obviously reduced, the body weight increase is obviously decelerated, and the internal organ fat content is obviously reduced. The oleanolic acid is added in the primary adipocyte culture liquid, and the decomposition of triglyceride can be obviously promoted. Therefore, the oleanolic acid can be used in medicine for treating the obesity and relevant diseases caused by the obesity, and in addition, side effects of possibly existing blood circulation free fatty acid increase during the body weight reduction, or even the insulin resistance and the like of the traditional weight reducing medicine can be overcome.
Description
Technical field
The present invention relates to the purposes of oleanolic acid, specifically refer to the application of oleanolic acid in the medicine of treatment obesity and the fat associated conditions that causes.
Background technology
At present, obesity has become a global health problem.If continue seriously to go down, obesity will soon surpass smoking, becomes the U.S.'s dead maximum unicity risk factor too early, reduces quality of life, increases social cost.According to the U.S. CDC statistics, there has been 1/3 U.S. adult to suffer from obesity, also have 1/3 people overweight, and obese degree increase year by year.A research in " JAMA " shows that 160,000 people of surpassing are arranged every year in the U.S. because fat " accident " death.Have scientist to claim, because the productivity and medical expense increase, on average each overweight people is annual can cause more than 7000 dollar burden to society.In recent years, owing to improving constantly of rapid development of economy and quality of life, middle national trouble obesity number is more and more, and what bring is severe complication and financial burden such as diabetes, cardiovascular disease.
Fat complex genesis, research worker has been carried out many-sided research to the pathogenesis of obesity, but the result is also not fully up to expectations.The fat method of treatment mainly contains the behavior therapy and pharmacotherapy at present.The behavior therapy mainly is to go on a diet and add large amount of exercise, and this method can temporarily reduce body fat, but is easy to bounce-back.Drug therapy mainly is the lipid mobilization of storage of adipocytes to be got into blood circulation carry out metabolism, yet this method usually causes the blood circulation free fatty even causes side effect such as insulin resistant.Fat formation mainly be since energy take the photograph the consumption of the National People's Congress in energy, unnecessary energy is stored in the body fat tissue with the triglyceride form, the generation of finally causeing fat.Therefore, merely triglyceride can not fundamentally be solved problem of obesity from adipose cell release, the decomposition that promotes triglyceride is fat direct, an effective and efficient manner of treatment.
(Oleanolic acid is a kind of natural triterpenoid OA), and is the aglucon of many saponin that its structural formula is seen Fig. 1 to oleanolic acid.Oleanolic acid is present in the various foods (rapeseed oil) in a large number, and is the composition of many plant leafs and rhizome, comprises that Olea europaea, Viscum album L., Aralia chinensis L and other surpass 120 kinds of natural plants.Oleanolic acid has had the use in more than 20 year historical as Effective Components of Chinese Herb, is mainly used in the treatment viral hepatitis.Discover that oleanolic acid can protect mice to avoid various hepatotoxicants and electrophilic thing, comprise the damage of carbon tetrachloride, acetaminophen, bromination benzene and thioacetamide etc.After giving oleanolic acid, oleanolic acid mainly is distributed in liver and at liver metabolism.Mice gives oleanolic acid in advance, can reduce the transaminase's that hepatotoxicant causes rising and suppress central necrosis of hepatic lobule.In addition, there is a large amount of research report to be rich in the natural drug of oleanolic acid and the synthesis of derivatives of oleanolic acid shows a series of pharmacology's function, comprises effects such as antiinflammatory, antitumor, promotion apoptosis.
Summary of the invention
The objective of the invention is oleanolic acid is applied to treat fat with fat relevant disease.
Be to realize the foregoing invention purpose, technical scheme of the present invention is following: a kind of oleanolic acid and purposes, be used for treating fat medicine or be used for treating the medicine of the disease that obesity causes.
Characteristics of the present invention are for using the oleanolic acid with the effectiveness of protecting the liver; Treatment obesity and associated conditions thereof; Compare with existing slimming medicine; Both guaranteed the effectiveness of fat-reducing, can bring into play the effectiveness that protects the liver of oleanolic acid again, and prevented that the blood circulation free fatty from raising even cause side effect such as insulin resistant.
Description of drawings
Fig. 1 is the oleanolic acid structural formula.
Fig. 2 is the blood sugar decreasing effect of oleanolic acid to the db/db mice
Fig. 3 is the phosphorylation figure of the db/db murine protein kinase b of oleanolic acid insulin stimulating.
Fig. 4 is the lose weight design sketch of oleanolic acid to the db/db mice.
Fig. 5 is that oleanolic acid increases former fat subsitutes cell glycerol release graphics.
The specific embodiment
Through instance the present invention is further specified below, its purpose is better to understand content of the present invention, and unrestricted protection scope of the present invention.
Embodiment
1. experimental apparatus
Electronic animal is claimed, blood sugar detection appearance (Johnson Co.), precise electronic balance, camera, 1ml syringe etc.
2. laboratory animal and material
2.1 laboratory animal
The SD rat, the cleaning level, male, body weight 180 ± 220g has The Fourth Military Medical University's Experimental Animal Center to provide.
2.2 experiment material
Normal saline, picric acid, blood sugar test paper, insulin, glycerol are measured test kit.
3. experimental technique
24 db/db mices (6-8 age in week) are divided into 3 groups at random: positive group: db/db mice; OA low dosage processed group: 10mg/kg OA; OA high dose processed group: 20mg/kg OA.(Wild type, WT) the db/m mice is made as normal control (8) to wild type.OA treatment group lumbar injection 10mg/kg or 20mg/kg OA (the administration solvent is the normal saline of 2%Tween 80).Positive group and matched group give the administration solvent of equal volume.Be 2 weeks experimental period.
Male SD rat (180-220g) dislocation is put to death, separate epididymal adipose, cultivate former fat subsitutes cell.In culture fluid, add 20 μ M and 40 μ M oleanolic acid respectively; Cultivated 24 as a child, with cell in 200r/min, centrifugal 30s, careful collecting cell culture fluid; Culture fluid comes deactivation glycerol catabolic enzyme to prevent the glycerol enzymolysis in 70 ℃ of heating 10min, and sample preservation is to be measured in-20 ℃.Measure the mM glycerol burst size that supernatant glycerol release fat decomposition data is expressed as every liter of adipose cell hematocrit (mmol/L packed cell volume, mmol/LPCV).
4. experimental result
4.1 it is as shown in Figure 2; The average fasting blood sugar of positive treated animal is 25.92 ± 2.32mmol/L; The average fasting blood sugar of low dosage oleanolic acid treatment treated animal is 19.80 ± 5.34mmol/L, and the average fasting blood sugar of high dose oleanolic acid treatment treated animal is 18.94 ± 1.32mmol/L.
4.2 as shown in Figure 3, oleanolic acid can obviously improve the insulin signaling conduction of db/db mice, significantly strengthens the protein kinase B phosphorylation level of insulin stimulating.
4.3 as shown in Figure 4, oleanolic acid obviously slows down the weight of animals increase.
4.4 as shown in Figure 5, oleanolic acid discharges obviously primarily cultured adipocytes glycerol to be increased.
It is thus clear that it is feasible that the present invention utilizes in the fat medicine of oleanolic acid treatment.
Claims (2)
1. the purposes of an oleanolic acid is characterized in that: be used for treating fat medicine.
2. the purposes of a kind of oleanolic acid according to claim 1 is characterized in that: the medicine that also is used for treating the disease that obesity causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101863470A CN102716134A (en) | 2012-06-07 | 2012-06-07 | Application of oleanolic acid to medicine for treating obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101863470A CN102716134A (en) | 2012-06-07 | 2012-06-07 | Application of oleanolic acid to medicine for treating obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102716134A true CN102716134A (en) | 2012-10-10 |
Family
ID=46942091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101863470A Pending CN102716134A (en) | 2012-06-07 | 2012-06-07 | Application of oleanolic acid to medicine for treating obesity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102716134A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585161A (en) * | 2013-10-25 | 2014-02-19 | 中国人民解放军第四军医大学 | Medicinal composition, and its application in preparation of medicines for treating obesity, insulin resistance and diabetes |
| CN105017374A (en) * | 2015-07-20 | 2015-11-04 | 山西大学 | Oleanonic acid lactone derivative and its preparation method and use |
| CN105777846A (en) * | 2016-03-15 | 2016-07-20 | 合肥华方医药科技有限公司 | Preparation method and medical application of OA (oleanolic acid) and BBR (berberine) conjugate |
| CN105770858A (en) * | 2016-03-18 | 2016-07-20 | 中南大学湘雅二医院 | Human-derived obesity inhibitory peptide |
| CN108938768A (en) * | 2018-07-25 | 2018-12-07 | 甘肃奇正实业集团有限公司 | A kind of raising Xianbei an ancient nationality in China spends or the method for Sibiraea angustata effect of weight reducing and obtained product and application |
-
2012
- 2012-06-07 CN CN2012101863470A patent/CN102716134A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 蔺美玲等: "齐墩果酸抑制高脂饮食肥胖大鼠体重的实验研究", 《成都医学院学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585161A (en) * | 2013-10-25 | 2014-02-19 | 中国人民解放军第四军医大学 | Medicinal composition, and its application in preparation of medicines for treating obesity, insulin resistance and diabetes |
| CN103585161B (en) * | 2013-10-25 | 2015-12-02 | 中国人民解放军第四军医大学 | Pharmaceutical composition and the application in preparation treatment obesity, insulin resistant and diabetes medicament thereof |
| CN105017374A (en) * | 2015-07-20 | 2015-11-04 | 山西大学 | Oleanonic acid lactone derivative and its preparation method and use |
| CN105777846A (en) * | 2016-03-15 | 2016-07-20 | 合肥华方医药科技有限公司 | Preparation method and medical application of OA (oleanolic acid) and BBR (berberine) conjugate |
| CN105770858A (en) * | 2016-03-18 | 2016-07-20 | 中南大学湘雅二医院 | Human-derived obesity inhibitory peptide |
| CN108938768A (en) * | 2018-07-25 | 2018-12-07 | 甘肃奇正实业集团有限公司 | A kind of raising Xianbei an ancient nationality in China spends or the method for Sibiraea angustata effect of weight reducing and obtained product and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duan et al. | Antifatigue Effect of Luteolin‐6‐C‐Neohesperidoside on Oxidative Stress Injury Induced by Forced Swimming of Rats through Modulation of Nrf2/ARE Signaling Pathways | |
| Yu et al. | In vitro and in vivo anti-inflammatory effects of ethanol extract from Acer tegmentosum | |
| Chen et al. | Osthole, a natural coumarin improves cognitive impairments and BBB dysfunction after transient global brain ischemia in C57 BL/6J mice: involvement of Nrf2 pathway | |
| CN102716134A (en) | Application of oleanolic acid to medicine for treating obesity | |
| CN103750339B (en) | Saussurea involucrate culture health-care food and application thereof | |
| CN102793741A (en) | Beautiful millettia root extract and application thereof | |
| Chien et al. | A Chinese Herbal Medicine, Jia‐Wei‐Xiao‐Yao‐San, Prevents Dimethylnitrosamine‐Induced Hepatic Fibrosis in Rats | |
| Zeng et al. | Laminaria japonica polysaccharides effectively inhibited the growth of nasopharyngeal carcinoma cells in vivo and in vitro study | |
| Abulizi et al. | Ganoderic acid alleviates chemotherapy-induced fatigue in mice bearing colon tumor | |
| Liu et al. | Antiallodynic and anti-hyperalgesia effects of Tiliacora triandra against cisplatin-induced peripheral neuropathy | |
| Liu et al. | Sesame oil therapeutically ameliorates cardiac hypertrophy by regulating hypokalemia in hypertensive rats | |
| CN102764262B (en) | Application of oleanolic acid and retinoic acid pharmaceutical composition in medicament for treating insulin resistance and diabetes | |
| Chiu et al. | Improvement of insulin resistance by Chlorella in fructose‐rich chow‐fed rats | |
| CN104366037A (en) | Aquatic product liver and gallbladder syndrome control feed additive and preparation method thereof | |
| Wang et al. | Intervention Study of Dictyophora Polysaccharides on Arsenic‐Induced Liver Fibrosis in SD Rats | |
| CN107213145A (en) | Application of the Rabdocetsin B in the product for suppressing esophageal squamous cell cancer cell multiplication is prepared | |
| CN101433329A (en) | Nutritive composition with health-care function | |
| CN103585161B (en) | Pharmaceutical composition and the application in preparation treatment obesity, insulin resistant and diabetes medicament thereof | |
| Son et al. | Medicinal herbs and their active compounds for fatty liver diseases | |
| CN103690519A (en) | Application of salvianolic acid A in preparation of medicine for treating tumour multi-drug resistance | |
| CN107961288A (en) | Application of the cordate houttuynia water extract in the medicine for improving aortic endothelial cell function is prepared | |
| CN103520244B (en) | Application of gynura procumbens extracts to preparation of liver injury prevention and cure preparations | |
| CN103271351B (en) | Oral giant salamander liquid for brain strengthening, and preparation method thereof | |
| CN103623282A (en) | Composition for relieving alcoholic liver injury | |
| Joshi et al. | Sportsmen’s energy package Cordyceps sinensis: Medicinal importance and responsible phytochemical constituents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121010 |